Why This Alzheimer’s Study Is Crushing Biogen Shares
Biogen shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 105
Why Pfizer Is Getting Deeper Into Gene Therapy
Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing certain diseases.
Pfizer Moves Over Half a Billion for Wilson Disease Treatment
Pfizer is looking to collaborate with Vivet on the development of its proprietary treatment for Wilson disease.
Bad News for AbbVie and Multiple Myeloma Patients
AbbVie and patients suffering from multiple myeloma have seen some additional bad news from the FDA.
What’s Next for Altimmune’s Influenza Vaccine
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Dermira’s Eczema Treatment Lebrikizumab Breaks Through
Dermira shares more than doubled on Monday after the firm announced midstage results from its Eczema study.
What Its Antiplatelet Reversal Agent Means for PhaseBio Going Forward
PhaseBio shares more than doubled on Monday after the firm released results from an early-stage clinical trial of its antiplatelet reversal agent.
5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential
We screened our 24/7 Wall St. research database and found five biotech stocks trading under the $10 level that could provide investors with some solid upside potential.
Can Karyopharm’s Myeloma Treatment Selinexor Pass Muster?
Karyopharm shares jumped on Friday after the firm announced an FDA update from the FDA on its treatment for myeloma.
How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?
Johnson & Johnson shares dipped on Thursday on news that a California jury awarded $29 million to a woman that claimed its talcum-powder-based products caused her cancer.
Vadadustat Makes the Case for Blockbuster Status After Japanese Chronic Kidney Disease Studies
Patients suffering anemia due to chronic kidney disease are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies.
Major Biotechs See a Rising Tide in Short Interest
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Big Pharma Short Interest Backs Off, With One Huge Exception
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
Great News for Adolescents with Moderate to Severe Atopic Dermatitis
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Why Investors Are Hyped for Tonix Pharma’s PTSD Late-Stage Trial
Tonix Pharma shares made a solid gain on Monday after the firm announced that it is beginning to enroll patients in its late-stage study of Tonmya for the treatment of post-traumatic stress disorder.